Skip to main content

Pfizer and BioNTech seek authorization of omicron-targeted booster for children aged 5 to 11

Pfizer and German partner BioNTech said Monday they're seeking Food and Drug Administration authorization for their omicron-targeting bivalent vaccine for use in children aged 5 to 11 years of age.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.